Ventura, David http://orcid.org/0000-0002-4346-2606
Rassek, Philipp
Schindler, Philipp
Akkurt, Burak Han
Bredensteiner, Linus
Bögemann, Martin
Schlack, Katrin
Seifert, Robert
Schäfers, Michael
Roll, Wolfgang
Rahbar, Kambiz
Funding for this research was provided by:
Universitätsklinikum Münster
Article History
Received: 19 May 2024
Accepted: 4 September 2024
First Online: 19 September 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Münster (No. 2019–711-f-S).
: Informed consent was obtained from all individual participants included in the study.
: KR reports honoraria from Advanced Accelerator Applications (AAA/Novartis), Bayer, Jahnsen Cielag, Amgen, Astrazeneca and Pharmtrace and a consultancy/advisory role with ABX GmbH, ABX-CRO, Bayer, and AAA/Novartis and UroTrials.MB receives honoraria from and has a consultancy/advisory role with Advanced Accelerator Applications (AAA/Novartis), Bayer, Janssen, Sanofi, Merck, MSD, BMS, Roche, Astellas, Exelixis, Pahrmtrace, Amgen, AstraZeneca, Eisai, Gilead, and EUSApharma.RS has received research support from Boehringer Ingelheim Funds and Else Kröner-Fresenius-Stiftung.All other authors have declared that no competing interest exists.